摘要
目的评价视网膜静脉阻塞（RVO）黄斑水肿玻璃体内注射雷珠单抗的疗效。方法回顾性分析我院2013年至2014年治疗的RVO黄斑水肿64例（72眼），玻璃体内注射雷珠单抗每月1次，连续3个月，据眼底缺血面积及新生血管情况进行视网膜激光光凝。记录注药前及注药后各时间点的视力、眼压及黄斑中心区视网膜厚度，随访6个月。结果视网膜分支静脉阻塞（BRVO）组黄斑与视网膜中央静脉阻塞（CRV0）相比，水肿程度，用药后改善较明显（F=253．500，P〈0．01），视力恢复较好（F=380．880，P〈0．01）。BRVO组就诊时间较早者，黄斑水肿改善较快（P〈0．01），视力恢复较好（P〈0．01）。结论早期玻璃体内注药对RVO引起的黄斑水肿效果好，视力恢复较好，且3个月后视力维持较好。
Objective To evaluate the clinical efficacy of intravitreal injection of ranibizumab （IVR） for the treatment of macular edema （CME） due to retinal vein occlusion. Methods The data of 72 eyes of 64 patients with retinal vein occlusion （ RVO ）, from 2013 to 2014, were collected and analyzed retrospectively. All patients received IVR monthly for 3 months. According to the retinal isehemia area and retinal neovascularzation received retinal photocoagulation. The thickness of macular, visual acuity and IOP of every time point before and after IVR were recorded. The followed time was 6 months. Results The degree of CME of branch retinal vein occlcusion（BRVO） group was lower than that of central retinal vein occlusion （CRVO） group. After IVR injection the BCVA improved better（ F = 253. 500, P 〈 0. 001 ）. In BRVO group, the earlier the appointment time, the quicker visual recovery and the better CME improved （ P 〈 0. 001 ）. Conclusion The patients with CME from RVO receive monthly intravitreal ranibizumab injection early. The earlier treatment the greater improvements in BCVA. After 3 months the visual acuity is preserved a longer duration.
出处
《中华眼外伤职业眼病杂志》
2017年第6期452-456,共5页
Chinese Journal of Ocular Trauma and Occupational Eye Disease
